LONA LeonaBio, Inc.
LeonaBio, Inc. (LONA) is expected to report earnings on November 13, 2026, after the market close. The consensus earnings estimate is a loss of $0.57 per share.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About LeonaBio, Inc.
LeonaBio Inc. is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. Its lead drug candidates include lasofoxifene and ATH-1105. LeonaBio Inc., formerly known as Athira Pharma Inc., is headquartered in the Seattle, Washington.
Sector
Healthcare
Industry
Biotechnology